REG - Renalytix PLC - Plan to Implement ADS Ratio Change

RenalytixAnnouncement

25/11/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251125:nRSY7856Ia&default-theme=true

RNS Number : 7856I  Renalytix PLC  25 November 2025

Renalytix plc

("Renalytix" or the "Company")

 

Renalytix Announces Plan to Implement ADS Ratio Change

 

LONDON and NEW YORK, 25 November 2025 - Renalytix plc (LSE: RENX) (OTCQB:
RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the
only FDA-approved and Medicare reimbursed prognostic test to support
early-stage risk assessment in chronic kidney disease, announces plans to
change the ratio of its American Depository Shares ("ADSs") to its ordinary
shares from one (1) ADS, representing two (2) ordinary shares, to one
(1) ADS representing fifty (50) ordinary shares (the "ADS Ratio"). The change
in the ADS Ratio is expected to become effective on or about 12 December 2025
(the "Effective Date").

 

For the Company's ADS holders, the change in the ADS Ratio has the same effect
as a one-for-twenty five reverse ADS split and will have no impact on an ADS
holder's proportional equity interest in the Company. The change in the ADS
Ratio is intended to further support the liquidity in the Company's ADSs,
reduce the cost and expenses of the ADS program to the Company and its
shareholders, and to provide future alternatives to regaining compliance with
the U.S. listing exchanges' minimum bid price requirements. On the Effective
Date, registered holders of the Company's ADSs held in certificated form will
be required on a mandatory basis to surrender their certificated ADSs to
Citibank, N.A., the depositary bank (the "Depositary"), for cancellation and
will receive one (1) new ADS in exchange for every twenty five (25) existing
ADSs surrendered. Holders of uncertificated ADSs in the Direct Registration
System (DRS) and The Depository Trust Company (DTC) will have their ADSs
automatically exchanged and need not take any action. The exchange of every
twenty five (25) then-held (existing) ADSs for one (1) new ADS will occur
automatically at the Effective Date, with the then-held ADSs being cancelled
and new ADSs being issued by the Depositary. The Company's ADSs will continue
to be traded on OTCQB under the ticker symbol "RNLXY."

 

No fractional new ADSs will be issued in connection with the change in the ADS
Ratio. Instead, fractional entitlements to new ADSs will be aggregated and
sold by the Depositary, and the net cash proceeds from the sale of the
fractional ADS entitlements (after deduction of fees, taxes, and expenses)
will be distributed to the applicable ADS holders by the Depositary.

 

As a result of the change in the ADS Ratio, the ADS trading price is expected
to increase proportionally, although the Company can give no assurance that
the ADS trading price after the change in the ADS Ratio will be proportionally
equal to or greater than the previous ADS trading price prior to the change or
that the change in the ADS Ratio will have any effect on the liquidity in the
Company's ADSs.

 

For further information, please contact:

 

 Renalytix plc                                         www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                                 Via Walbrook PR

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)             Tel: +44 (0)20 3470 0470
 Jeff Keating / David Hignell (Corporate Finance)

 Vadim Alexandre (Corporate Broking)

 Oberon Capital (Joint Broker)                         Tel: +44 (0)20 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited        Tel: +44 (0)20 7933 8780 or renalytix@walbrookpr.com
                            (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings                         Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of kidney
disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest
barriers to controlling cost and suffering in the United States and the United
Kingdom's medical system, affecting over 14 million and 8 million people,
respectively. After five years of development and clinical validation,
kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic
tool capable of understanding a patient's risk with kidney disease early where
treatment has maximal effect. kidneyintelX.dkd is now being deployed across
large physician group practices and health systems in select regions of the
United States.

 

The over 15,000 patients that have been tested by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In patient
populations where kidneyintelX.dkd has been deployed, a demonstrated and
significant increase in diagnosis, prognosis, and treatment rates have been
recorded. kidneyintelX.dkd now has full reimbursement established by Medicare,
the largest insurance payer in the United States, at $950 per reportable
result. kidneyintelX.dkd is also recommended for use in the international
chronic kidney disease clinical guidelines (KDIGO).

 

KidneyIntelX is based on technology developed by Mount Sinai faculty and
licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and
equity owners in the Company. In addition, the Icahn School of Medicine at
Mount Sinai has equity ownership in Renalytix. For information about the
kidneyintelX,dkd test, visit kidneyintelx.com (http://kidneyintelx.com/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AIMPPGMCGUPAGAC



            Copyright 2019 Regulatory News Service, all rights reserved